Artelo biosciences reports fiscal 2022 year-end financial results and provides business update

$17.5 million in cash and marketable securities as of december 31, 2022; expected to support operations into second half of 2024 $17.5 million in cash and marketable securities as of december 31, 2022; expected to support operations into second half of 2024
ARTL Ratings Summary
ARTL Quant Ranking